Your browser doesn't support javascript.
loading
Cancers of the corpus uteri treated in South Australian public hospitals: Trends in clinical management and survival across three decades.
Roder, David; Selva-Nayagam, Sudarsha; Paramasivam, Sellvakumaran; Keefe, Dorothy; Olver, Ian; Miller, Caroline; Buckley, Elizabeth; Powell, Kate; Fusco, Kellie; Buranyi-Trevarton, Dianne; Oehler, Martin.
Afiliación
  • Roder D; Cancer Research Institute, University of South Australia, Adelaide, SA, Australia.
  • Selva-Nayagam S; Medical Oncology, Royal Adelaide Hospital Cancer Centre, Adelaide, SA, Australia.
  • Paramasivam S; Gynaecological Oncology, Flinders Medical Centre, Adelaide, SA, Australia.
  • Keefe D; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia.
  • Olver I; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia.
  • Miller C; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia.
  • Buckley E; Health Policy Centre, South Australian Health & Medical Research Institute, Adelaide, SA, Australia.
  • Powell K; Cancer Research Institute, University of South Australia, Adelaide, SA, Australia.
  • Fusco K; SA Clinical Cancer Registry, SA Health, Adelaide, SA, Australia.
  • Buranyi-Trevarton D; Cancer Research Institute, University of South Australia, Adelaide, SA, Australia.
  • Oehler M; SA Clinical Cancer Registry, SA Health, Adelaide, SA, Australia.
Eur J Cancer Care (Engl) ; 29(5): e13281, 2020 Sep.
Article en En | MEDLINE | ID: mdl-32639088
ABSTRACT

OBJECTIVE:

To investigate treatment and survival over three decades.

METHODS:

Clinical registry data from three major public hospitals analysed using Kaplan-Meier product-limit estimates and multivariate proportional hazard regression to determine disease-specific survival.

RESULTS:

Five-year survival increased from 75% to 84%. The adjusted hazard ratio (HR, 95% CI) was 0.56 (0.41, 0.77) for 2010-2016 compared with 1984-1989 and was higher for ages 80+ years; more advanced stages; poorly differentiated tumours; and complex mixed epithelial and mesenchymal tumours and sarcomas. Treatment was by surgery (92%), radiotherapy (33%), chemotherapy (12%) and hormone therapy (10%). Adjusted analyses showed radiotherapy and hormone therapy were less common from 1990 and chemotherapy more common for 2010-2016. Treatment likelihood was lower for ages ≥80 years, mixed epithelial and mesenchymal tumours receiving surgery and chemotherapy, but higher for radiotherapy. Advanced cancers (FIGO stage IV) had less surgery but more non-surgical treatments. Marginal evidence presented of more hormone therapy for high socio-economic areas.

CONCLUSIONS:

Survival was equivalent to national figures for Australia and the United States, but potentially higher than for England and Wales. Cases aged 80+ years had less care and poorer survival. Findings illustrate the complementary roles of hospital and population-based registries in local service evaluation.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Límite: Aged80 / Female / Humans / Newborn País/Región como asunto: Oceania Idioma: En Revista: Eur J Cancer Care (Engl) Asunto de la revista: ENFERMAGEM / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Límite: Aged80 / Female / Humans / Newborn País/Región como asunto: Oceania Idioma: En Revista: Eur J Cancer Care (Engl) Asunto de la revista: ENFERMAGEM / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Australia